Yoshida, E. | Toumi, M. |
The Japanese generic drug market is not well developed. The generic volume share is 20% of the total market vs. 74% and 64% in the USA and UK. The slow uptake of generics is often explained by the “Brand Lover” profile of Japan. No formal review of drug policy has been undertaken to understand the slow uptake of generics.